SCHEMBL334642

SCHEMBL334642

CCOc1ccc(C(C)=O)cc1CN1CCCCC1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.74
ALDH1A1 P00352 6/20 0.74
PKM P14618 2/20 0.74
TSHR P16473 2/20 0.74
HTT P42858 2/20 0.74
MAPT P10636 2/20 0.74
KMT2A Q03164 3/20 0.70
MEN1 O00255 2/20 0.70
RAD52 P43351 1/20 0.55
LMNA P02545 1/20 0.54
CREBBP Q92793 1/20 0.52
HRH3 Q9Y5N1 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPK1 P28482 1/20 0.50
MAPK10 P53779 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334977 0.87 ALDH1A1 (0.59) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL29910129 0.86 L3MBTL1 (0.97) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL336150 0.86 L3MBTL1 (0.97) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL335214 0.85 L3MBTL1 (0.95) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL334483 0.79 L3MBTL1 (0.67) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL11619459 0.78 L3MBTL1 (0.65) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL11619637 0.78 L3MBTL1 (0.65) L3MBTL1ALDH1A1PKMTSHRHTT
SCHEMBL27542208 0.78 KDM4E (0.74) ALDH1A1TSHRKMT2AMEN1
SCHEMBL14667296 0.77 CREBBP (0.64) L3MBTL1ALDH1A1PKMHTTMAPT
Hydrochloric Acid SCHEMBL11619986 0.77 L3MBTL1 (0.67) L3MBTL1ALDH1A1PKMTSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 L3MBTL1 2853/4885ALDH1A1 1939/4885PKM 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.